# EDGAR Filing Document

**Accession Number:** 0000352665
**File Stem:** 0000940400-25-005282
**Filing Date:** 2025-10
**Character Count:** 33895
**Document Hash:** 71e929a60725fb147b4ef8b034757ee8
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000940400-25-005282.hdr.sgml**: 20251027

**ACCESSION NUMBER**: 0000940400-25-005282

**CONFORMED SUBMISSION TYPE**: NPORT-P

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20250829

**FILED AS OF DATE**: 20251027

**DATE AS OF CHANGE**: 20251027

**PERIOD START**: 20251130

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** PRUDENTIAL SECTOR FUNDS, INC.
- **CENTRAL INDEX KEY:** 0000352665

**ORGANIZATION NAME:**
- **EIN:** 133071974
- **STATE OF INCORPORATION:** MD
- **FISCAL YEAR END:** 1130

**FILING VALUES:**
- **FORM TYPE:** NPORT-P
- **SEC ACT:** 1940 Act
- **SEC FILE NUMBER:** 811-03175
- **FILM NUMBER:** 251419343

**BUSINESS ADDRESS:**
- **STREET 1:** 655 BROAD STREET
- **STREET 2:** 6TH FLOOR
- **CITY:** NEWARK
- **STATE:** NJ
- **ZIP:** 07102
- **BUSINESS PHONE:** (973) 802-5032

**MAIL ADDRESS:**
- **STREET 1:** 655 BROAD STREET
- **STREET 2:** 6TH FLOOR
- **CITY:** NEWARK
- **STATE:** NJ
- **ZIP:** 07102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRUDENTIAL SECTOR FUNDS INC d/b/a JENNISONDRYDEN SECTOR FUNDS
- **DATE OF NAME CHANGE:** 20090113

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PRUDENTIAL SECTOR FUNDS INC
- **DATE OF NAME CHANGE:** 20080902

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** JENNISON SECTOR FUNDS INC
- **DATE OF NAME CHANGE:** 20030716

## Series and Classes Contracts Data

### PGIM Jennison Health Sciences Fund (Series ID: S000004380)

| Class ID   | Class Name   | Ticker Symbol   |
|:---|:---|:---|
| C000012121 | Class A      | PHLAX           |
| C000012123 | Class C      | PHLCX           |
| C000012124 | Class Z      | PHSZX           |
| C000110073 | Class R      | PJHRX           |
| C000165347 | Class R6     | PHLQX           |

## Nport-Ex

### PGIM Jennison Health Sciences Fund

### Schedule of Investments (unaudited)
as of August 31, 2025

---

| | | |
|:---|:---|:---|
| **Description** | &nbsp;&nbsp;**Shares** | &nbsp;&nbsp;**Value** |
| **Long-Term Investments 94.3%** | **Long-Term Investments 94.3%** | **Long-Term Investments 94.3%** |
| **Common Stocks 94.3%** | **Common Stocks 94.3%** | **Common Stocks 94.3%** |
| **Biotechnology 38.9%** | **Biotechnology 38.9%** | **Biotechnology 38.9%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Alnylam Pharmaceuticals, Inc.\*(a) | &nbsp;&nbsp;&nbsp;&nbsp;83185 | &nbsp;&nbsp; $37142934 |
| &nbsp;&nbsp;&nbsp;&nbsp;Apellis Pharmaceuticals, Inc.\* | 1432003 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;39480323 |
| &nbsp;&nbsp;&nbsp;&nbsp;Arcutis Biotherapeutics, Inc.\*(a) | 2269514 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;35222857 |
| &nbsp;&nbsp;&nbsp;&nbsp;Argenx SE (Netherlands), ADR\* | &nbsp;&nbsp;&nbsp;&nbsp;78802 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;56122784 |
| &nbsp;&nbsp;&nbsp;&nbsp;BeOne Medicines Ltd. (China), ADR\*(a) | &nbsp;&nbsp;&nbsp;&nbsp;41474 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12693118 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cabaletta Bio, Inc.\*(a) | 3518102 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5101248 |
| &nbsp;&nbsp;&nbsp;&nbsp;Caris Life Sciences, Inc.\*(a) | &nbsp;&nbsp;&nbsp;&nbsp;50295 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1930825 |
| &nbsp;&nbsp;&nbsp;&nbsp;Gilead Sciences, Inc. | &nbsp;&nbsp;&nbsp;437030 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49371279 |
| &nbsp;&nbsp;&nbsp;&nbsp;Insmed, Inc.\* | &nbsp;&nbsp;&nbsp;234427 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;31905515 |
| &nbsp;&nbsp;&nbsp;&nbsp;Kymera Therapeutics, Inc.\*(a) | &nbsp;&nbsp;&nbsp;523510 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21568612 |
| &nbsp;&nbsp;&nbsp;&nbsp;Metsera, Inc.\*(a) | &nbsp;&nbsp;&nbsp;221101 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7802654 |
| &nbsp;&nbsp;&nbsp;&nbsp;Natera, Inc.\* | &nbsp;&nbsp;&nbsp;&nbsp;41292 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6947379 |
| &nbsp;&nbsp;&nbsp;&nbsp;Neurocrine Biosciences, Inc.\* | &nbsp;&nbsp;&nbsp;381142 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;53207423 |
| &nbsp;&nbsp;&nbsp;&nbsp;Newamsterdam Pharma Co. NV (Netherlands)\*(a) | &nbsp;&nbsp;&nbsp;777280 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18693584 |
| &nbsp;&nbsp;&nbsp;&nbsp;Rhythm Pharmaceuticals, Inc.\* | &nbsp;&nbsp;&nbsp;133038 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13722870 |
| &nbsp;&nbsp;&nbsp;&nbsp;Scholar Rock Holding Corp.\*(a) | &nbsp;&nbsp;&nbsp;158182 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5164642 |
| &nbsp;&nbsp;&nbsp;&nbsp;Sionna Therapeutics, Inc.\*(a) | &nbsp;&nbsp;&nbsp;553942 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;13638052 |
| &nbsp;&nbsp;&nbsp;&nbsp;Soleno Therapeutics, Inc.\* | &nbsp;&nbsp;&nbsp;&nbsp;81298 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;5501436 |
| &nbsp;&nbsp;&nbsp;&nbsp;Travere Therapeutics, Inc.\* | &nbsp;&nbsp;&nbsp;393263 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;6882103 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vaxcyte, Inc.\* | &nbsp;&nbsp;&nbsp;585342 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18022680 |
| &nbsp;&nbsp;&nbsp;&nbsp;Vertex Pharmaceuticals, Inc.\* | &nbsp;&nbsp;&nbsp;150218 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58738242 |
| &nbsp;&nbsp;&nbsp;&nbsp;Xenon Pharmaceuticals, Inc. (Canada)\* | &nbsp;&nbsp;&nbsp;522446 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20223885 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;519084445 |
| **Health Care Services 4.4%** | **Health Care Services 4.4%** | **Health Care Services 4.4%** |
| &nbsp;&nbsp;&nbsp;&nbsp;CVS Health Corp. | &nbsp;&nbsp;&nbsp;502332 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;36745586 |
| &nbsp;&nbsp;&nbsp;&nbsp;GeneDx Holdings Corp.\* | &nbsp;&nbsp;&nbsp;&nbsp;60734 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;7864446 |
| &nbsp;&nbsp;&nbsp;&nbsp;Guardant Health, Inc.\* | &nbsp;&nbsp;&nbsp;144677 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;9754123 |
| &nbsp;&nbsp;&nbsp;&nbsp;Omada Health, Inc.\*(a) | &nbsp;&nbsp;&nbsp;171831 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;4070676 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;58434831 |
| **Health Care Equipment 9.9%** | **Health Care Equipment 9.9%** | **Health Care Equipment 9.9%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Beta Bionics, Inc.\*(a) | &nbsp;&nbsp;&nbsp;&nbsp;43415 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;817938 |
| &nbsp;&nbsp;&nbsp;&nbsp;Dexcom, Inc.\* | &nbsp;&nbsp;&nbsp;249266 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;18779700 |
| &nbsp;&nbsp;&nbsp;&nbsp;Edwards Lifesciences Corp.\* | &nbsp;&nbsp;&nbsp;263382 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21423492 |
| &nbsp;&nbsp;&nbsp;&nbsp;GE HealthCare Technologies, Inc. | &nbsp;&nbsp;&nbsp;358242 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;26413183 |
| &nbsp;&nbsp;&nbsp;&nbsp;Intuitive Surgical, Inc.\* | &nbsp;&nbsp;&nbsp;117504 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;55614056 |
| &nbsp;&nbsp;&nbsp;&nbsp;Kestra Medical Technologies Ltd.\*(a) | &nbsp;&nbsp;&nbsp;&nbsp;77529 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1251318 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tandem Diabetes Care, Inc.\*(a) | &nbsp;&nbsp;&nbsp;649862 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;8129774 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;132429461 |
| **Health Care Supplies 1.4%** | **Health Care Supplies 1.4%** | **Health Care Supplies 1.4%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Solventum Corp.\* | &nbsp;&nbsp;&nbsp;260461 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19037094 |
| **Health Care Technology 0.1%** | **Health Care Technology 0.1%** | **Health Care Technology 0.1%** |
| &nbsp;&nbsp;&nbsp;&nbsp;HeartFlow, Inc.\*(a) | &nbsp;&nbsp;&nbsp;&nbsp;56764 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1788066 |
| **Life Sciences Tools & Services 14.1%** | **Life Sciences Tools & Services 14.1%** | **Life Sciences Tools & Services 14.1%** |
| &nbsp;&nbsp;&nbsp;&nbsp;Danaher Corp. | &nbsp;&nbsp;&nbsp;238151 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;49016239 |
| &nbsp;&nbsp;&nbsp;&nbsp;Lonza Group AG (Switzerland) | &nbsp;&nbsp;&nbsp;&nbsp;52839 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;37499253 |
| &nbsp;&nbsp;&nbsp;&nbsp;Revvity, Inc.(a) | &nbsp;&nbsp;&nbsp;219203 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;19752382 |
| &nbsp;&nbsp;&nbsp;&nbsp;Stevanato Group SpA (Italy)(a) | &nbsp;&nbsp;&nbsp;523209 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;12039039 |
| &nbsp;&nbsp;&nbsp;&nbsp;Thermo Fisher Scientific, Inc. | &nbsp;&nbsp;&nbsp;141931 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;69932242 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;188239155 |

---

------

### PGIM Jennison Health Sciences Fund

### Schedule of Investments (unaudited) (continued)
as of August 31, 2025

---

| | | |
|:---|:---|:---|
| **Description** | &nbsp;&nbsp;**Shares** | &nbsp;&nbsp;**Value** |
| **Common Stocks (Continued)** | **Common Stocks (Continued)** | **Common Stocks (Continued)** |
| **Managed Health Care 2.9%** | **Managed Health Care 2.9%** | **Managed Health Care 2.9%** |
| &nbsp;&nbsp;&nbsp;&nbsp;UnitedHealth Group, Inc. | 126565 | &nbsp;&nbsp; $39218697 |
| **Pharmaceuticals 22.6%** | **Pharmaceuticals 22.6%** | **Pharmaceuticals 22.6%** |
| &nbsp;&nbsp;&nbsp;&nbsp;AstraZeneca PLC (United Kingdom), ADR | 469600 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;37521040 |
| &nbsp;&nbsp;&nbsp;&nbsp;Crinetics Pharmaceuticals, Inc.\* | 675458 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;20932444 |
| &nbsp;&nbsp;&nbsp;&nbsp;Eli Lilly & Co. | 238385 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;174636083 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tarsus Pharmaceuticals, Inc.\*(a) | 382765 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;22422374 |
| &nbsp;&nbsp;&nbsp;&nbsp;UCB SA (Belgium) | 197591 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;46350679 |
|  |  | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;301862620 |
| **Total Common Stocks<br> (cost $864,394,874)** | **Total Common Stocks<br> (cost $864,394,874)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1260094369 |

---

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;**Units** |  |
| **Warrants\* 0.0%** | **Warrants\* 0.0%** | **Warrants\* 0.0%** |
| **Biotechnology** | **Biotechnology** | **Biotechnology** |
| &nbsp;&nbsp;&nbsp;&nbsp;Cabaletta Bio, Inc., expiring 09/11/26<br> (cost $0) | 2139298 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;21 |
| **Total Long-Term Investments<br> (cost $864,394,874)** | **Total Long-Term Investments<br> (cost $864,394,874)** | &nbsp;&nbsp;&nbsp;&nbsp;1260094390 |

---

---

| | | |
|:---|:---|:---|
|  | &nbsp;&nbsp;**Shares** |  |
| **Short-Term Investments 11.9%** | **Short-Term Investments 11.9%** | **Short-Term Investments 11.9%** |
| **Affiliated Mutual Funds** | **Affiliated Mutual Funds** | **Affiliated Mutual Funds** |
| &nbsp;&nbsp;&nbsp;&nbsp;PGIM Core Government Money Market Fund (7-day effective yield 4.483%)(wb) | &nbsp;&nbsp;76988501 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;76988501 |
| &nbsp;&nbsp;&nbsp;&nbsp;PGIM Institutional Money Market Fund (7-day effective yield 4.526%)<br> (cost $81,807,826; includes $81,515,245 of cash collateral for securities on loan)(b)(wb) | &nbsp;&nbsp;81868021 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;81810713 |
| **Total Short-Term Investments<br> (cost $158,796,327)** | **Total Short-Term Investments<br> (cost $158,796,327)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;158799214 |
| **TOTAL INVESTMENTS 106.2%<br> (cost $1,023,191,201)** | **TOTAL INVESTMENTS 106.2%<br> (cost $1,023,191,201)** | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;1418893604 |
| Liabilities in excess of other assets (6.2)% | Liabilities in excess of other assets (6.2)% | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(82397119) |
| **Net Assets 100.0%** | **Net Assets 100.0%** | &nbsp;&nbsp;&nbsp;&nbsp;$1336496485 |

---

------

Below is a list of the abbreviation(s) used in the quarterly schedule of portfolio holdings:

ADR—American Depositary Receipt

\* Non-income producing security.

(a) All or a portion of security is on loan. The aggregate market value of such securities, including those sold and pending settlement, is $79,082,741; cash collateral of $81,515,245 (included in liabilities) was received with which the Fund purchased highly liquid short-term investments. In the event of significant appreciation in value of securities on loan on the last business day of the reporting period, the Fund may reflect a collateral value that is less than the market value of the loaned securities and such shortfall is remedied the following business day.

(b) Represents security, or portion thereof, purchased with cash collateral received for securities on loan and includes dividend reinvestment.

(wb) Represents an investment in a Fund affiliated with the Manager.

Other information regarding the Fund is available in the Fund's most recent Report to Shareholders. This information is available on the Securities and Exchange Commission's website (www.sec.gov).

## Form NPORT-P: Monthly Portfolio Investments Report

### NPORT-P: Part A: General Information

**Item A.1. Information about the Registrant.**

- **a. Name of Registrant:** Prudential Sector Funds, Inc.

- **b. Investment Company Act file number:** 811-03175

- **c. CIK number of Registrant:** 0000352665

- **d. LEI of Registrant:** 549300IPCXL88G4QUI19

- **e. Address and telephone number of Registrant.**

  - **Street Address 1:** 655 Broad Street

  - **City:** Newark

  - **State:** NJ

  - **Foreign country:** US

  - **Zip / Postal Code:** 07102-4077

  - **Telephone number:** 1-800-225-1852

**Item A.2. Information about the Series.**

- **a. Name of Series:** PGIM Jennison Health Sciences Fund

- **b. EDGAR series identifier (if any):** S000004380

- **c. LEI of Series:** S41LI155RNUZ4KJ9CN75

**Item A.3. Reporting period.**

- **a. Date of fiscal year-end:** 2025-11-30

- **b. Date as of which information is reported:** 2025-08-29

**Item A.4. Final filing**

Does the Fund anticipate that this will be its final filing on Form N-PORT? **No**

### Fund Information

**Total Assets:** $1424217830.20

**Total Liabilities:** $86645508.70

**Net Assets:** $1337572321.50

**Monthly Return Information**

| Class               | Month 1 Return (%)   | Month 2 Return (%)   | Month 3 Return (%)   |
|:---|:---|:---|:---|
| Class ID C000012121 | 3.84%                | -0.87%               | 4.89%                |
| Class ID C000012123 | 3.78%                | -1.02%               | 4.88%                |
| Class ID C000012124 | 3.88%                | -0.87%               | 4.94%                |
| Class ID C000110073 | 3.82%                | -0.91%               | 4.84%                |
| Class ID C000165347 | 3.89%                | -0.86%               | 4.94%                |

**Monthly Gains & Losses**

| Period   | Net Realized Gain/Loss   | Net Unrealized Appreciation/Depreciation   |
|:---|:---|:---|
| Month 1  | $27961879.45             | $23773271.44                               |
| Month 2  | $14991583.04             | $-25878480.74                              |
| Month 3  | $32556503.66             | $30771187.67                               |

### Schedule of Portfolio Investments

| Name                                             | Title                                            | Identifiers                                   | Payoff Profile   | Asset Category   | Issuer Category   | Country   |   Balance | Units   | Value (USD)   | % of Net Assets   | Maturity Date   | Coupon Type   | Annualized Rate (%)   | Restricted?   |   Fair Value Level | Lending Status   |
|:---|:---|:---|:---|:---|:---|:---|---:|:---|:---|:---|:---|:---|:---|:---|---:|:---|
| Newamsterdam Pharma Co NV                        | Newamsterdam Pharma Co NV                        | CUSIP: 000000000<br>LEI: 984500B6549TF6E14D36 | Long             | EC               | CORP              | NL        |    777280 | NS      | $18693584.00  | 1.40%             |  |  |  | No            |                  1 | On Loan: —       |
| Cabaletta Bio Inc                                | Cabaletta Bio Inc                                | CUSIP: 12674W109<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   3518102 | NS      | $5101247.90   | 0.38%             |  |  |  | No            |                  1 | On Loan: —       |
| Tandem Diabetes Care Inc                         | Tandem Diabetes Care Inc                         | CUSIP: 875372203<br>LEI: 549300JEPFOD0K4D3I05 | Long             | EC               | CORP              | US        |    649862 | NS      | $8129773.62   | 0.61%             |  |  |  | No            |                  1 | On Loan: —       |
| Argenx SE                                        | Argenx SE                                        | CUSIP: 04016X101<br>LEI: 7245009C5FZE6G9ODQ71 | Long             | EC               | CORP              | NL        |     78802 | NS      | $56122784.40  | 4.20%             |  |  |  | No            |                  1 | On Loan: No      |
| Neurocrine Biosciences Inc                       | Neurocrine Biosciences Inc                       | CUSIP: 64125C109<br>LEI: 549300FECER0XBN49756 | Long             | EC               | CORP              | US        |    381142 | NS      | $53207423.20  | 3.98%             |  |  |  | No            |                  1 | On Loan: No      |
| Natera Inc                                       | Natera Inc                                       | CUSIP: 632307104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     41292 | NS      | $6947379.00   | 0.52%             |  |  |  | No            |                  1 | On Loan: No      |
| HeartFlow Inc                                    | HeartFlow Inc                                    | CUSIP: 42238D107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     56764 | NS      | $1788066.00   | 0.13%             |  |  |  | No            |                  1 | On Loan: —       |
| Beta Bionics Inc                                 | Beta Bionics Inc                                 | CUSIP: 08659B102<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     43415 | NS      | $817938.60    | 0.06%             |  |  |  | No            |                  1 | On Loan: —       |
| Thermo Fisher Scientific Inc                     | Thermo Fisher Scientific Inc                     | CUSIP: 883556102<br>LEI: HCHV7422L5HDJZCRFL38 | Long             | EC               | CORP              | US        |    141931 | NS      | $69932242.32  | 5.23%             |  |  |  | No            |                  1 | On Loan: No      |
| Soleno Therapeutics Inc                          | Soleno Therapeutics Inc                          | CUSIP: 834203309<br>LEI: 5493003LCY77N7FXK844 | Long             | EC               | CORP              | US        |     81298 | NS      | $5501435.66   | 0.41%             |  |  |  | No            |                  1 | On Loan: No      |
| Stevanato Group SpA                              | Stevanato Group SpA                              | CUSIP: 000000000<br>LEI: 81560033F7E1CD477507 | Long             | EC               | CORP              | IT        |    523209 | NS      | $12039039.09  | 0.90%             |  |  |  | No            |                  1 | On Loan: —       |
| Crinetics Pharmaceuticals Inc                    | Crinetics Pharmaceuticals Inc                    | CUSIP: 22663K107<br>LEI: 549300Q1CNFXK5P31D28 | Long             | EC               | CORP              | US        |    675458 | NS      | $20932443.42  | 1.56%             |  |  |  | No            |                  1 | On Loan: No      |
| Dexcom Inc                                       | Dexcom Inc                                       | CUSIP: 252131107<br>LEI: 549300YSK3QDSFR5EU59 | Long             | EC               | CORP              | US        |    249266 | NS      | $18779700.44  | 1.40%             |  |  |  | No            |                  1 | On Loan: No      |
| Caris Life Sciences Inc                          | Caris Life Sciences Inc                          | CUSIP: 142152107<br>LEI: 549300LX5LO78M5VPY43 | Long             | EC               | CORP              | US        |     50295 | NS      | $1930825.05   | 0.14%             |  |  |  | No            |                  1 | On Loan: —       |
| Travere Therapeutics Inc                         | Travere Therapeutics Inc                         | CUSIP: 89422G107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    393263 | NS      | $6882102.50   | 0.51%             |  |  |  | No            |                  1 | On Loan: No      |
| Apellis Pharmaceuticals Inc                      | Apellis Pharmaceuticals Inc                      | CUSIP: 03753U106<br>LEI: 254900HS0ZFRXXSB9D42 | Long             | EC               | CORP              | US        |   1432003 | NS      | $39480322.71  | 2.95%             |  |  |  | No            |                  1 | On Loan: No      |
| Tarsus Pharmaceuticals Inc                       | Tarsus Pharmaceuticals Inc                       | CUSIP: 87650L103<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    382765 | NS      | $22422373.70  | 1.68%             |  |  |  | No            |                  1 | On Loan: —       |
| Kymera Therapeutics Inc                          | Kymera Therapeutics Inc                          | CUSIP: 501575104<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    523510 | NS      | $21568612.00  | 1.61%             |  |  |  | No            |                  1 | On Loan: —       |
| CVS Health Corp                                  | CVS Health Corp                                  | CUSIP: 126650100<br>LEI: 549300EJG376EN5NQE29 | Long             | EC               | CORP              | US        |    502332 | NS      | $36745585.80  | 2.75%             |  |  |  | No            |                  1 | On Loan: No      |
| Omada Health Inc                                 | Omada Health Inc                                 | CUSIP: 68170A108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    171831 | NS      | $4070676.39   | 0.30%             |  |  |  | No            |                  1 | On Loan: —       |
| Danaher Corp                                     | Danaher Corp                                     | CUSIP: 235851102<br>LEI: S4BKK9OTCEWQ3YHPFM11 | Long             | EC               | CORP              | US        |    238151 | NS      | $49016238.82  | 3.66%             |  |  |  | No            |                  1 | On Loan: No      |
| UnitedHealth Group Inc                           | UnitedHealth Group Inc                           | CUSIP: 91324P102<br>LEI: 549300GHBMY8T5GXDE41 | Long             | EC               | CORP              | US        |    126565 | NS      | $39218696.55  | 2.93%             |  |  |  | No            |                  1 | On Loan: No      |
| Insmed Inc                                       | Insmed Inc                                       | CUSIP: 457669307<br>LEI: 529900Q55QAG41CCAC11 | Long             | EC               | CORP              | US        |    234427 | NS      | $31905514.70  | 2.39%             |  |  |  | No            |                  1 | On Loan: No      |
| Vertex Pharmaceuticals Inc                       | Vertex Pharmaceuticals Inc                       | CUSIP: 92532F100<br>LEI: 54930015RAQRRZ5ZGJ91 | Long             | EC               | CORP              | US        |    150218 | NS      | $58738242.36  | 4.39%             |  |  |  | No            |                  1 | On Loan: No      |
| (PIPA070) PGIM Core Government Money Market Fund | (PIPA070) PGIM Core Government Money Market Fund | CUSIP: 000000000<br>LEI: N/A                  | Long             | STIV             | RF                | US        |  78016255 | NS      | $78016254.57  | 5.83%             |  |  |  | No            |                  1 | On Loan: No      |
| Sionna Therapeutics Inc                          | Sionna Therapeutics Inc                          | CUSIP: 829401108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    553942 | NS      | $13638052.04  | 1.02%             |  |  |  | No            |                  1 | On Loan: —       |
| Intuitive Surgical Inc                           | Intuitive Surgical Inc                           | CUSIP: 46120E602<br>LEI: 54930052SRG011710797 | Long             | EC               | CORP              | US        |    117504 | NS      | $55614055.68  | 4.16%             |  |  |  | No            |                  1 | On Loan: No      |
| Gilead Sciences Inc                              | Gilead Sciences Inc                              | CUSIP: 375558103<br>LEI: 549300WTZWR07K8MNV44 | Long             | EC               | CORP              | US        |    437030 | NS      | $49371279.10  | 3.69%             |  |  |  | No            |                  1 | On Loan: No      |
| Revvity Inc                                      | Revvity Inc                                      | CUSIP: 714046109<br>LEI: 549300IKL1SDPFI7N655 | Long             | EC               | CORP              | US        |    219203 | NS      | $19752382.33  | 1.48%             |  |  |  | No            |                  1 | On Loan: —       |
| AstraZeneca PLC                                  | AstraZeneca PLC                                  | CUSIP: 046353108<br>LEI: PY6ZZQWO2IZFZC3IOL08 | Long             | EC               | CORP              | GB        |    469600 | NS      | $37521040.00  | 2.81%             |  |  |  | No            |                  1 | On Loan: No      |
| GE HealthCare Technologies Inc                   | GE HealthCare Technologies Inc                   | CUSIP: 36266G107<br>LEI: 549300OI9J7XOWZMUN85 | Long             | EC               | CORP              | US        |    358242 | NS      | $26413182.66  | 1.97%             |  |  |  | No            |                  1 | On Loan: No      |
| CABALETTA BIO INC WARRANT                        | CABALETTA BIO INC WARRANT                        | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   2139298 | NS      | $21.39        | 0.00%             |  |  |  | No            |                  2 | On Loan: No      |
| Alnylam Pharmaceuticals Inc                      | Alnylam Pharmaceuticals Inc                      | CUSIP: 02043Q107<br>LEI: 529900S3ZI14OWRJII50 | Long             | EC               | CORP              | US        |     83185 | NS      | $37142934.35  | 2.78%             |  |  |  | No            |                  1 | On Loan: —       |
| Xenon Pharmaceuticals Inc                        | Xenon Pharmaceuticals Inc                        | CUSIP: 98420N105<br>LEI: 549300XV44Q9Z1MIPQ03 | Long             | EC               | CORP              | CA        |    522446 | NS      | $20223884.66  | 1.51%             |  |  |  | No            |                  1 | On Loan: No      |
| UCB SA                                           | UCB SA                                           | CUSIP: 000000000<br>LEI: 2138008J191VLSGY5A09 | Long             | EC               | CORP              | BE        |    197591 | NS      | $46350679.18  | 3.47%             |  |  |  | No            |                  2 | On Loan: No      |
| Kestra Medical Technologies Lt                   | Kestra Medical Technologies Ltd                  | CUSIP: 000000000<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     77529 | NS      | $1251318.06   | 0.09%             |  |  |  | No            |                  1 | On Loan: —       |
| Guardant Health Inc                              | Guardant Health Inc                              | CUSIP: 40131M109<br>LEI: 254900M8C3E5VC8BR186 | Long             | EC               | CORP              | US        |    144677 | NS      | $9754123.34   | 0.73%             |  |  |  | No            |                  1 | On Loan: No      |
| Metsera Inc                                      | Metsera Inc                                      | CUSIP: 59267L107<br>LEI: N/A                  | Long             | EC               | CORP              | US        |    221101 | NS      | $7802654.29   | 0.58%             |  |  |  | No            |                  1 | On Loan: —       |
| PGIM Institutional Money Market Fund - D         | PGIM Institutional Money Market Fund - D         | CUSIP: 000000000<br>LEI: N/A                  | Long             | STIV             | RF                | US        |  83884746 | NS      | $83834414.80  | 6.27%             |  |  |  | No            |                  1 | On Loan: No      |
| BeOne Medicines Ltd                              | BeOne Medicines Ltd                              | CUSIP: 07725L102<br>LEI: 549300JFUK6FRD5MH739 | Long             | EC               | CORP              | US        |     41474 | NS      | $12693117.70  | 0.95%             |  |  |  | No            |                  1 | On Loan: —       |
| Arcutis Biotherapeutics Inc                      | Arcutis Biotherapeutics Inc                      | CUSIP: 03969K108<br>LEI: N/A                  | Long             | EC               | CORP              | US        |   2269514 | NS      | $35222857.28  | 2.63%             |  |  |  | No            |                  1 | On Loan: —       |
| Edwards Lifesciences Corp                        | Edwards Lifesciences Corp                        | CUSIP: 28176E108<br>LEI: YA13X31F3V31L8TMPR58 | Long             | EC               | CORP              | US        |    263382 | NS      | $21423491.88  | 1.60%             |  |  |  | No            |                  1 | On Loan: No      |
| GeneDx Holdings Corp                             | GeneDx Holdings Corp                             | CUSIP: 81663L200<br>LEI: N/A                  | Long             | EC               | CORP              | US        |     60734 | NS      | $7864445.66   | 0.59%             |  |  |  | No            |                  1 | On Loan: No      |
| Lonza Group AG                                   | Lonza Group AG                                   | CUSIP: 000000000<br>LEI: 549300EFW4H2TCZ71055 | Long             | EC               | CORP              | CH        |     52839 | NS      | $37499252.76  | 2.80%             |  |  |  | No            |                  2 | On Loan: No      |
| Scholar Rock Holding Corp                        | Scholar Rock Holding Corp                        | CUSIP: 80706P103<br>LEI: 549300Z1FLPGL4OWJ459 | Long             | EC               | CORP              | US        |    158182 | NS      | $5164642.30   | 0.39%             |  |  |  | No            |                  1 | On Loan: —       |
| Eli Lilly & Co                                   | Eli Lilly & Co                                   | CUSIP: 532457108<br>LEI: FRDRIPF3EKNDJ2CQJL29 | Long             | EC               | CORP              | US        |    238385 | NS      | $174636083.30 | 13.06%            |  |  |  | No            |                  1 | On Loan: No      |
| Rhythm Pharmaceuticals Inc                       | Rhythm Pharmaceuticals Inc                       | CUSIP: 76243J105<br>LEI: 529900JPNWXQ8DPLA551 | Long             | EC               | CORP              | US        |    133038 | NS      | $13722869.70  | 1.03%             |  |  |  | No            |                  1 | On Loan: No      |
| Solventum Corp                                   | Solventum Corp                                   | CUSIP: 83444M101<br>LEI: 254900I70403OSGY4M28 | Long             | EC               | CORP              | US        |    260461 | NS      | $19037094.49  | 1.42%             |  |  |  | No            |                  1 | On Loan: No      |
| Vaxcyte Inc                                      | Vaxcyte Inc                                      | CUSIP: 92243G108<br>LEI: 254900M7NMHTGASX8D95 | Long             | EC               | CORP              | US        |    585342 | NS      | $18022680.18  | 1.35%             |  |  |  | No            |                  1 | On Loan: No      |

### Signature

**Date Signed:** 2025-10-27

**Name of Applicant:** Prudential Sector Funds, Inc.

**Signature:** Christian J. Kelly

**Name of Signer:** Christian J. Kelly

**Title:** Chief Financial Officer